

Freeform Search

Database:

- US Pre-Grant Publication Full-Text Database
- US Patents Full-Text Database
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Term:




Display: Documents in Display Format: Starting with Number

Generate: Hit List Hit Count Side by Side Image

Search History

DATE: Friday, July 16, 2004 [Printable Copy](#) [Create Case](#)

Set Name **Query**

side by side

Hit Count **Set Name**

result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<u>L15</u>	L14 same 112	2	<u>L15</u>
<u>L14</u>	modi\$ or revers\$	3611935	<u>L14</u>
<u>L13</u>	L12 same l6	6	<u>L13</u>
<u>L12</u>	l9 with 11	21	<u>L12</u>
<u>L11</u>	l9 same l3	4	<u>L11</u>
<u>L10</u>	L9 with l3	3	<u>L10</u>
<u>L9</u>	surface potential or zeta potential	23015	<u>L9</u>
<u>L8</u>	L7 same l5	28	<u>L8</u>
<u>L7</u>	surface	7796737	<u>L7</u>
<u>L6</u>	polyanionic or anionic or negativ\$	1210811	<u>L6</u>
<u>L5</u>	L4 with l3	221	<u>L5</u>
<u>L4</u>	DNA or nucleic or plasmid	246149	<u>L4</u>
<u>L3</u>	L2 with 11	778	<u>L3</u>
<u>L2</u>	neutral\$	688451	<u>L2</u>
<u>L1</u>	cationic lipid or cationic amphiphile or cationic liposome	9388	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#) [Generate Collection](#) [Print](#)

L8: Entry 6 of 28

File: PGPB

Nov 14, 2002

DOCUMENT-IDENTIFIER: US 20020169138 A1

TITLE: Delivery vehicles for bioactive agents and uses thereof

Summary of Invention Paragraph:

[0006] Additionally, it is known that the transfection activity of cationic liposomes is interfered with by serum components which presumably neutralize the unpaired positive charges in the complexes which are essential for binding of DNA/lipid complexes to the cell surface. See, e.g., Felgner, P. L. et al. *Nature* 337:387-388, 1989; Felgner, P. L., et al. *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1987; and Gao, X. and Huang, L., *Biochem. Biophys. Res. Comm.* 179:280-285, 1991. Because of this problem alone, the use of cationic liposomes for gene transfer is limited to the situation where a minimal amount of serum is present; accordingly, cationic liposomes as an *in vivo* delivery system are of limited value.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#) [Generate Collection](#) [Print](#)

L11: Entry 2 of 4

File: PGPB

Mar 21, 2002

DOCUMENT-IDENTIFIER: US 20020034537 A1

TITLE: Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites

Summary of Invention Paragraph:

[0018] This McDonald et al. patent describes the use of cationic liposomes that may include both neutral and cationic lipids, for example, having 5 mol % or more of cationic lipids or, specifically, having neutral lipids in an amount of about 45% and cationic lipids in an amount of about 55%. While McDonald et al. indicates that cationic liposomes have a zeta potential of greater than 0 mV, this patent does not teach any specific zeta potential or isoelectric point, or ranges thereof, as being preferred for the selective targeting of angiogenic endothelial cells. McDonald et al. also does not indicate the preferred upper limit of cationic lipid to use in the cationic liposome composition for selective targeting of angiogenic endothelial cells. 100161 Thurston et al. (1998) also describes the targeting of endothelial cells in tumors and chronic inflammation in mice using cationic liposomes. Thurston uses cationic liposomes having 55 mol % of cationic component. Thurston does not disclose the specific zeta potential or isoelectric point or ranges thereof for selective targeting of endothelial cells in tumors or chronic inflammation in mice.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)